Tumor evolution selectively inactivates the core microRNA machinery for immune evasion.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
01 12 2021
Historique:
received: 25 04 2021
accepted: 15 11 2021
entrez: 2 12 2021
pubmed: 3 12 2021
medline: 29 12 2021
Statut: epublish

Résumé

Cancer cells acquire genetic heterogeneity to escape from immune surveillance during tumor evolution, but a systematic approach to distinguish driver from passenger mutations is lacking. Here we investigate the impact of different immune pressure on tumor clonal dynamics and immune evasion mechanism, by combining massive parallel sequencing of immune edited tumors and CRISPR library screens in syngeneic mouse tumor model and co-culture system. We find that the core microRNA (miRNA) biogenesis and targeting machinery maintains the sensitivity of cancer cells to PD-1-independent T cell-mediated cytotoxicity. Genetic inactivation of the machinery or re-introduction of ANKRD52 frequent patient mutations dampens the JAK-STAT-interferon-γ signaling and antigen presentation in cancer cells, largely by abolishing miR-155-targeted silencing of suppressor of cytokine signaling 1 (SOCS1). Expression of each miRNA machinery component strongly correlates with intratumoral T cell infiltration in nearly all human cancer types. Our data indicate that the evolutionarily conserved miRNA pathway can be exploited by cancer cells to escape from T cell-mediated elimination and immunotherapy.

Identifiants

pubmed: 34853298
doi: 10.1038/s41467-021-27331-3
pii: 10.1038/s41467-021-27331-3
pmc: PMC8636623
doi:

Substances chimiques

Chemokines 0
MIRN155 microRNA, human 0
MicroRNAs 0
PDCD1 protein, human 0
Pdcd1 protein, mouse 0
Programmed Cell Death 1 Receptor 0
Suppressor of Cytokine Signaling 1 Protein 0
Interferon-gamma 82115-62-6
Phosphoprotein Phosphatases EC 3.1.3.16

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

7003

Informations de copyright

© 2021. The Author(s).

Références

Nat Rev Immunol. 2021 Jun 21;:
pubmed: 34155388
Nucleic Acids Res. 2012 May;40(10):4288-97
pubmed: 22287627
Cell. 2021 Feb 4;184(3):596-614.e14
pubmed: 33508232
Nat Biotechnol. 2020 Jul;38(7):824-844
pubmed: 32572269
Cancer Discov. 2020 Dec;10(12):1912-1933
pubmed: 32887696
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
Nat Rev Cancer. 2015 Jun;15(6):321-33
pubmed: 25998712
Nat Rev Cancer. 2019 Mar;19(3):133-150
pubmed: 30755690
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Nature. 2019 May;569(7757):503-508
pubmed: 31068700
Science. 2018 Feb 16;359(6377):770-775
pubmed: 29301958
Bioinformatics. 2019 Jul 15;35(14):i436-i445
pubmed: 31510660
F1000Res. 2014 Apr 24;3:95
pubmed: 24860646
Science. 2018 Feb 16;359(6377):801-806
pubmed: 29301960
Cell. 2017 Nov 2;171(4):934-949.e16
pubmed: 29033130
Science. 2015 Oct 9;350(6257):207-211
pubmed: 26359337
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
Cancer Discov. 2020 Feb;10(2):270-287
pubmed: 31744829
Nat Commun. 2017 Oct 26;8(1):1136
pubmed: 29070816
J Exp Med. 2002 Oct 7;196(7):999-1005
pubmed: 12370261
Nat Cell Biol. 2016 Jul;18(7):790-802
pubmed: 27295554
Trends Immunol. 2001 May;22(5):265-8
pubmed: 11323285
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Nature. 2017 Feb 9;542(7640):197-202
pubmed: 28114302
Nat Genet. 2007 May;39(5):673-7
pubmed: 17401365
Science. 2009 Aug 21;325(5943):965
pubmed: 19556464
N Engl J Med. 2008 Dec 18;359(25):2641-50
pubmed: 19092150
Clin Cancer Res. 2015 Oct 15;21(20):4607-18
pubmed: 25979485
Cancer Cell. 2015 Feb 9;27(2):298-311
pubmed: 25670083
Bioinformatics. 2007 Jan 15;23(2):257-8
pubmed: 17098774
Int J Mol Epidemiol Genet. 2011 Jan 1;2(1):9-18
pubmed: 21552306
Cancer Res. 2010 Oct 15;70(20):7841-50
pubmed: 20805302
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
Nature. 2017 Aug 31;548(7669):537-542
pubmed: 28783722
Immunity. 2009 Jan 16;30(1):80-91
pubmed: 19144316
Immunity. 2020 Jan 14;52(1):17-35
pubmed: 31940268
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Cancer Cell. 2010 Oct 19;18(4):303-15
pubmed: 20951941
J Clin Invest. 2020 Oct 1;130(10):5257-5271
pubmed: 32603315
Nat Protoc. 2019 Mar;14(3):756-780
pubmed: 30710114
Nat Immunol. 2017 Mar 22;18(4):374-384
pubmed: 28323260
Nature. 2019 Jan;565(7737):43-48
pubmed: 30559380
Nature. 2017 Jul 27;547(7664):413-418
pubmed: 28723893
Cancer Discov. 2017 Feb;7(2):188-201
pubmed: 27903500
J Biol Chem. 2021 Jan-Jun;296:100264
pubmed: 33837743
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
Nat Protoc. 2017 Apr;12(4):828-863
pubmed: 28333914
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Oncogene. 2015 Aug 27;34(35):4647-55
pubmed: 25486434
Genes Dev. 2009 Dec 1;23(23):2700-4
pubmed: 19903759
Immunity. 2019 Jun 18;50(6):1347-1349
pubmed: 31216458
Nature. 2015 Jul 9;523(7559):183-188
pubmed: 26131937
Nucleic Acids Res. 2020 May 21;48(9):4681-4697
pubmed: 32297952
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
N Engl J Med. 2012 Jan 19;366(3):234-42
pubmed: 22187960
Cell. 2012 Jul 20;150(2):251-63
pubmed: 22817889
Nat Commun. 2017 May 31;8:15440
pubmed: 28561041
Genes Chromosomes Cancer. 2019 Apr;58(4):244-253
pubmed: 30578699
Nature. 2020 Oct;586(7827):120-126
pubmed: 32968282
Genome Med. 2020 Oct 6;12(1):86
pubmed: 33023656
Cell. 2019 Aug 8;178(4):933-948.e14
pubmed: 31398344
Immunity. 2020 Jan 14;52(1):55-81
pubmed: 31940273
Science. 2019 Jun 07;364(6444):
pubmed: 31171663
Clin Cancer Res. 2018 Feb 15;24(4):794-806
pubmed: 29242316
Nat Rev Cancer. 2014 Oct;14(10):662-72
pubmed: 25176334
Nat Rev Immunol. 2018 Mar;18(3):153-167
pubmed: 28990585
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
Nature. 2019 Mar;567(7749):479-485
pubmed: 30894752
Science. 2019 Jun 28;364(6447):
pubmed: 31249028
Cell. 2015 Mar 12;160(6):1246-60
pubmed: 25748654
Nat Commun. 2020 Jan 30;11(1):602
pubmed: 32001684
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514
pubmed: 32442275
Cancer Cell. 2015 Feb 9;27(2):286-97
pubmed: 25670082

Auteurs

Tian-Yu Song (TY)

Gene Editing Center, School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai, China.
Life Sciences Institute, Zhejiang University, Hangzhou, Zhejiang, China.

Min Long (M)

Gene Editing Center, School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Life Sciences Institute, Zhejiang University, Hangzhou, Zhejiang, China.

Hai-Xin Zhao (HX)

Oncology and Immunology Unit, WuXi Biology, WuXi AppTec (Shanghai) Co, Ltd, Shanghai, China.

Miao-Wen Zou (MW)

Gene Editing Center, School of Life Science and Technology, ShanghaiTech University, Shanghai, China.

Hong-Jie Fan (HJ)

Gene Editing Center, School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
University of Chinese Academy of Sciences, 100049, Beijing, China.

Yang Liu (Y)

Gene Editing Center, School of Life Science and Technology, ShanghaiTech University, Shanghai, China.

Chen-Lu Geng (CL)

Gene Editing Center, School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Life Sciences Institute, Zhejiang University, Hangzhou, Zhejiang, China.

Min-Fang Song (MF)

Gene Editing Center, School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai, China.
University of Chinese Academy of Sciences, 100049, Beijing, China.

Yu-Feng Liu (YF)

Gene Editing Center, School of Life Science and Technology, ShanghaiTech University, Shanghai, China.

Jun-Yi Chen (JY)

Gene Editing Center, School of Life Science and Technology, ShanghaiTech University, Shanghai, China.

Yu-Lin Yang (YL)

Oncology and Immunology Unit, WuXi Biology, WuXi AppTec (Shanghai) Co, Ltd, Shanghai, China.

Wen-Rong Zhou (WR)

Oncology and Immunology Unit, WuXi Biology, WuXi AppTec (Shanghai) Co, Ltd, Shanghai, China.

Da-Wei Huang (DW)

Oncology and Immunology Unit, WuXi Biology, WuXi AppTec (Shanghai) Co, Ltd, Shanghai, China.

Bo Peng (B)

Gene Editing Center, School of Life Science and Technology, ShanghaiTech University, Shanghai, China.

Zhen-Gang Peng (ZG)

Oncology and Immunology Unit, WuXi Biology, WuXi AppTec (Shanghai) Co, Ltd, Shanghai, China.

Yong Cang (Y)

Gene Editing Center, School of Life Science and Technology, ShanghaiTech University, Shanghai, China. cangyong@shanghaitech.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH